We exclusively represent Absolute Antibody, U.K in Kenya, a company dedicated in offering research grade biosimilars (monoclonal antibodies and Fc fusion proteins) manufactured using proprietary recombinant platform. Our research grade biosimilars are research tools allowing for the study and evaluation of biological processes circumventing the need to purchase costly and difficult to source therapeutic grade biologics, which is currently the only available option. Moreover these biosimilar antibodies are free of excipients and/or additives found in the therapeutic formulations that are extremely difficult to control for in experimental settings.
Absolute Antibody research grade biosimilars can be used as controls:
- To benchmark novel biotherapeutics (biologics) for pre-clinical lead identification
- For the development of potency assays.
Custom options available for isotype switching, species switching, subtype switching & antibody reformatting
|Absolute Antibody||Trastuzumab | Muromonab | Campath-1H | Rituximab | Infliximab | Daclizumab | Basiliximab | Cetuximab | Satumomab | Acritumomab | Abaciximab | Eculizumab | Efalizumab | Clenoliximab | Ruplizumab | Matuzumab | Humicade | Volociximab and Oxelumab | Volociximab|